For media inquiries, contact us at +44 (0) 20 7821 2840 or email at firstname.lastname@example.org.
|16 Nov 2016||Sunovion Pharmaceuticals Europe Ltd. and NewBridge Pharmaceuticals Announce Agreement for Distribution of Latuda®▼(lurasidone) in the Gulf Cooperation Council Region|
|7 June 2016||Sunovion Pharmaceuticals Europe Ltd. and Medicines Optimisation Innovation Centre (MOIC) form a partnership for Mental Health|
|15 Oct 2015||Sunovion Celebrates Five-Year Anniversary Milestone|
|17 Mar 2015||All Wales Medicines Strategy Group Recommends Atypical Antipsychotic LATUDA® (lurasidone) as a Treatment Option for Schizophrenia in Adults|
|13 Oct 2014||Scottish Medicines Consortium Recommends LATUDA® (lurasidone), an Atypical Antipsychotic Agent for Adults with Schizophrenia, as a New Treatment Offering a Combination of Efficacy with Tolerability|
|21 Aug 2014||Latuda® (lurasidone), a New Atypical Antipsychotic Agent for Adults with Schizophrenia, Now Available in the UK, Offers a Combination of Efficacy with Tolerability|
|21 Jul 2014||Sunovion Pharmaceuticals Europe Ltd. Announces Data Showing Long-Term Treatment with Latuda® (lurasidone) Was Associated with a Significantly Lower Risk of Metabolic Syndrome Compared with Risperidone|
|31 Mar 2014||Sunovion Pharmaceuticals Europe Announce the European Marketing Authorisation for Latuda® (lurasidone) - a New Atypical Antipsychotic Medication for Adults with Schizophrenia|
|27 Jan 2014||Dainippon Sumitomo Pharma and Takeda Receive Positive CHMP Opinion for Lurasidone - a New Atypical Antipsychotic Medication for Adults with Schizophrenia|
|9 Oct 2013||Five Scientific Posters Supporting the Efficacy and Tolerability of Once-Daily Lurasidone – A New Atypical Antipsychotic treatment for Adults with Schizophrenia|
|2 Apr 2013||Sunovion Europe Announces New Name|
|25 Oct 2012||DSPE Regulatory Update: Acceptance of the European Medicines Agency Submission for an Atypical Antipsychotic Agent Lurasidone|
|18 Mar 2011||DSPE's Support for Japan's Disaster Relief Effort|
|17 Nov 2009||DSPE is awarded prestigious ‘Investors in People’ Standard|
If you would like details about Sumitomo Dainippon Pharma's global news please visit Sumitomo Dainippon Pharma News Releases. If you would like details about Sunovion Pharmaceutical Inc.'s news releases, please visit Sunovion Pharmaceutical Inc. News Releases.